Abstract Introduction. HPRT1 is a Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) coding gene, mutations of which cause, among other diseases, Lesch-Nyhan syndrome. LNS is a severe X-linked recessive neurological disorder. Alignment shows 98.6% homology of human and murine protein sequences. Objectives. We assume that murine model of this human disease should be developed. So, our purpose is to create a transgenic mouse model of Lesch-Nyhan syndrome by CRISPR/Cas9 genome editing system. Methods. The BLAST was used to find homologous mutation in murine HPRT1 gene comparing to Human one. X-ray crystallographic structural model of the HPRT1 was used as template for M4T Raptor algorithm to generate predicted structure of mutated protein. Models were visualized in PyMol (Schrodinger, Portland, OR). Lack of enzymatic activity of the HGPRT could be caused via troubled homodimerization. Absence of the aliphatic Valine could be the reason of the hindered monomers interaction. Genetic construction based on the px330 plasmid was brought using microinjection method in mouse fertilized ovum for producing primary transgenic organisms. Results. The CRISPR/Cas9 system was specifically designed to carry out mutations in HPRT. The resulting genetic construct was introduced into the fertilized mouse ovum to obtain primary transgenic organisms. This mouse was obtained at the Institute of Biology of the Russian Academy of Sciences. Conclusion. Homologous mutation in human and murine HPRT1 gene resulting into comparable conformational change in the protein model structure was revealed, so murine personalized model of the Lesch-Nyhan syndrome could be developed. Structural changes can be further studied to provide treatment strategy for people suffering from Lesch-Nyhan syndrome. This study was supported by Russian Science Foundation (Grant #17-75-20249).
Read full abstract